0001104659-23-120767.txt : 20231122 0001104659-23-120767.hdr.sgml : 20231122 20231122162459 ACCESSION NUMBER: 0001104659-23-120767 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231120 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231122 DATE AS OF CHANGE: 20231122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PaxMedica, Inc. CENTRAL INDEX KEY: 0001811623 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41475 FILM NUMBER: 231433816 BUSINESS ADDRESS: STREET 1: 303 SOUTH BROADWAY, SUITE 125 CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 914-987-2876 MAIL ADDRESS: STREET 1: 303 SOUTH BROADWAY, SUITE 125 CITY: TARRYTOWN STATE: NY ZIP: 10591 8-K 1 tm2331441d1_8k.htm FORM 8-K
false 0001811623 0001811623 2023-11-20 2023-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 20, 2023

 

PaxMedica, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-41475 85-0870387
(State or other jurisdiction
of incorporation)		 (Commission File Number) (IRS Employer
Identification No.)

 

303 South Broadway, Suite 125
Tarrytown, NY		 10591
(Address of principal executive offices) (Zip Code)

 

(914) 987-2876

(Registrant’s telephone number, including area code)

 

n/a

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, par value $0.0001 per share   PXMD   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01.

 

Entry Into a Material Definitive Agreement.

 

On November 20, 2023, PaxMedica, Inc. (the “Company”) priced its publicly marketed public offering of (i) 2,237,304 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), together with common stock purchase warrants (the “Common Stock Purchase Warrants”) to purchase 2,237,304 shares of Common Stock at a combined public offering price of $1.30 per Share and accompanying Common Stock Purchase Warrant and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 3,147,311 shares of Common Stock, together with Common Stock Purchase Warrants to purchase 3,147,311 shares of Common Stock at a combined public offering price of $1.2999 per Pre-Funded Warrant and accompanying Common Stock Purchase Warrant.

 

Subject to certain ownership limitations described in the Common Stock Purchase Warrants, the Common Stock Purchase Warrants have an exercise price of $1.30 per share of Common Stock, are exercisable upon issuance and will expire five years from the date of issuance. The exercise price of the Common Stock Purchase Warrants will be subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in the Common Stock Purchase Warrants.

 

Each Pre-Funded Warrant represents the right to purchase one share of Common Stock at an exercise price of $0.0001 per share. Subject to certain ownership limitations described in the Pre-Funded Warrants, the Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Stock Purchase Warrants and the Pre-Funded Warrants provide that holders will have the right to participate in any rights offering or distribution of assets, and will have the right to receive certain consideration in fundamental transactions, together with the holders of Common Stock on an as-exercised basis. In addition, upon a fundamental transaction, the holder of the Common Stock Purchase Warrants shall have the right to receive payment in cash, or under certain circumstances in other consideration, from the Company at the Black Scholes value as described in the Common Stock Purchase Warrants. A holder will not have the right to exercise any portion of the Common Stock Purchase Warrants or the Pre-Funded Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Stock Purchase Warrants or the Pre-Funded Warrants, respectively. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to the Company, provided that any increase in such percentage shall not be effective until 61 days after such notice. If not previously exercised in full, at the expiration of their terms, the Common Stock Purchase Warrants will be automatically exercised via cashless exercise.

 

In connection with the offering, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors. The Purchase Agreement contains customary representations and warranties of the Company, termination rights of the parties, and certain indemnification obligations of the Company and ongoing covenants of the Company, including a prohibition on issuance of Common Stock or securities convertible or exchangeable into Common Stock by the Company for a period of 60 days after the closing date of the offering and a prohibition on the Company entering into variable rate transactions for a period of 180 days after the closing date of the offering, subject to certain exceptions.

 

The net proceeds to the Company from the offering were approximately $6.3 million, after deducting Placement Agent’s fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to repay in full the approximately $0.2 million outstanding under the convertible promissory note held by Lind Global Fund II LP, to advance the Company’s development programs and for general corporate purposes.

 

 

 

 

The public offering was made pursuant to the Company’s effective registration statement on Form S-1 (Registration No. 333-275416) previously filed with and declared effective by the Securities and Exchange Commission on November 20, 2023, and a preliminary and final prospectus thereunder. The closing of the offering took place on November 22, 2023.

 

The Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) as exclusive placement agent for the public offering. The Placement Agent did not purchase or sell any securities, nor was it required to arrange the purchase or sale of any minimum number or dollar amount of securities. The Placement Agent agreed to use its reasonable best efforts to arrange for the sale of the securities in the offering. The Company paid the Placement Agent an aggregate cash fee equal to 6.5% of the gross proceeds received by the Company from such offering. The Company also reimbursed the Placement Agent for non-accountable fees and expenses in an amount up to $50,000, its legal fees and expenses and other out-of-pocket expenses in the amount of up to $100,000, and its clearing expenses in the amount of $15,950. The Company also agreed to issue to the Placement Agent or its designees warrants to purchase up to 4.0% of the of aggregate number of Shares and Pre-Funded Warrants sold in the offering (the “Placement Agent Warrants”). The Placement Agent Warrants have substantially the same terms as the Common Stock Purchase Warrants, except that the Placement Agent Warrants have an exercise price equal to $1.625 and have a term of five years from the commencement of sales of the offering.

 

The foregoing is only a summary of the Common Stock Purchase Warrants, the Pre-Funded Warrants, the Placement Agent Warrants and the Purchase Agreement and does not purport to be a complete description thereof. Such descriptions are qualified in their entirety by reference to the Form of Common Stock Purchase Warrant, the Form of Pre-Funded Warrant, the Form of Placement Agent Warrant and the Form of Purchase Agreement, copies of which are incorporated by reference as Exhibits 4.1, 4.2, 4.3 and 10.1, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

 

Item 8.01.

 

Other Events.

 

On November 20, 2023, the Company issued a press release announcing that the Company had priced the offering of the Shares, Pre-Funded Warrants and Common Stock Purchase Warrants. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

 

 

 

Item 9.01.

 

Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
Exhibit 4.1 Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.7 to the Registration Statement on Form S-1 filed on November 9, 2023).
Exhibit 4.2 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.8 to the Registration Statement on Form S-1 filed on November 9, 2023).
Exhibit 4.3 Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.9 to the Registration Statement on Form S-1 filed on November 9, 2023).
Exhibit 10.1 Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1 filed on November 9, 2023).
Exhibit 99.1 Press release issued November 20, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PaxMedica, Inc.
     
     
  By: /s/ Howard J. Weisman
  Name: Howard J. Weisman
  Title: Chief Executive Officer

 

Date: November 22, 2023

 

 

 

 EX-99.1 2 tm2331441d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

PaxMedica Announces Pricing of $7.0 Million Public Offering

 

TARRYTOWN, New York, Nov. 20, 2023 (ACCESSWIRE) PaxMedica, Inc. (NASDAQ: PXMD) (“PaxMedica” or the “Company”), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $1.30 per share, will be exercisable immediately upon issuance and will expire five years after the initial exercise date. The closing of the offering is expected to occur on or about November 22, 2023, subject to the satisfaction of customary closing conditions.

 

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

 

Total gross proceeds to the Company from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $7.0 million. The Company intends to use the net proceeds from this offering to repay in full the approximately $0.2 million outstanding under the convertible promissory note held by Lind Global Fund II LP, to advance the Company’s development programs and for general corporate purposes.

 

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-275416), which was declared effective by the Securities and Exchange Commission (the “SEC”) on November 20, 2023. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

 

About PaxMedica, Inc.

 

 

PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders, including Autism Spectrum Disorder (ASD) and Human African Trypanosomiasis (HAT). Our portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD and HAT treatment solutions. Our ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions.

 

 

 

 

Forward-Looking Statements:

 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. The use of words such as “will,” “expect,” or “intend” and other similar expressions are intended to identify such forward-looking statements. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Such forward-looking statements include, but are not limited to, the ability of the Company to close the offering, the expected timing of closing, the expected gross proceeds and the use of proceeds from the offering. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and set forth in the company's SEC filings, including the risks found in the section entitled “Risk Factors” in PaxMedica’s most recent Annual Report on Form 10-K and subsequent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in any subsequent reports filed with the SEC. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

 

Contacts

  

PaxMedica, Inc.
303 S Broadway,
Suite 125.
Tarrytown, NY 10591
www.paxmedica.com

 

Media Contact
media@paxmedica.com

 

Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
ir@paxmedica.com
www.paxmedica.com/investors

 

 

 

 

 

 EX-101.SCH 3 pxmd-20231120.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pxmd-20231120_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 pxmd-20231120_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 20, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 20, 2023
Entity File Number 001-41475
Entity Registrant Name PaxMedica, Inc.
Entity Central Index Key 0001811623
Entity Tax Identification Number 85-0870387
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 303 South Broadway
Entity Address, Address Line Two Suite 125
Entity Address, City or Town Tarrytown
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10591
City Area Code 914
Local Phone Number 987-2876
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol PXMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 tm2331441d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001811623 2023-11-20 2023-11-20 iso4217:USD shares iso4217:USD shares false 0001811623 8-K 2023-11-20 PaxMedica, Inc. DE 001-41475 85-0870387 303 South Broadway Suite 125 Tarrytown NY 10591 914 987-2876 false false false false Common Stock, par value $0.0001 per share PXMD NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>] M9!:G%C:^? MVZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZF ML6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._< M]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/ M'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0 MXIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/ M4$L#!!0 ( !V#=E&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% M 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF& M!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " =@W9799!YDAD! #/ P $P %M#;VYT96YT7U1Y M<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[: M2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)* MM9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO. M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( !V#=E<'04UB@0 +$ M 0 " 0 !D;V-0&UL4$L! A0#% M @ '8-V5XP2FX3M *P( !$ ( !KP &1O8U!R;W!S M+V-O&UL4$L! A0#% @ '8-V5YE&PO=V]R:W-H965T&UL4$L! A0#% @ '8-V5Y^@&_"Q @ X@P T M ( !R0P 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ '8-V5R0>FZ*M ^ $ !H M ( ![A$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !TQ( %M#;VYT96YT7U1Y ><&5S72YX;6Q02P4& D "0 ^ @ '10 end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://paxmedica.com/role/Cover Cover Cover 1 false false All Reports Book All Reports pxmd-20231120.xsd pxmd-20231120_lab.xml pxmd-20231120_pre.xml tm2331441d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2331441d1_8k.htm": { "nsprefix": "pxmd", "nsuri": "http://paxmedica.com/20231120", "dts": { "schema": { "local": [ "pxmd-20231120.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "pxmd-20231120_lab.xml" ] }, "presentationLink": { "local": [ "pxmd-20231120_pre.xml" ] }, "inline": { "local": [ "tm2331441d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://paxmedica.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2331441d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2331441d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://paxmedica.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-23-120767-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-120767-xbrl.zip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end